Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ALLR with free AI briefings, catalyst countdowns, and dilution alerts.

ALLR · Allarity Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$17M Cash on Hand
14.4mo Cash Runway
Follow ALLR by email Get an email when ALLR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ALLR, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
PARP/Tankyrase Inhibitor 2X-121 Advanced Ovarian Cancer Phase 2 · NCT03878849 Recruiting
Fas Receptor Agonist APO010 Relapsed/Refractory Multiple Myeloma Phase 1/2 · NCT03196947 Terminated
Irofulven Metastatic Castration-Resistant Prostate Cancer Patients Phase 2 · NCT03643107 Completed
LiPlaCis Phase 1: Advanced or Refractory Solid Tumours Phase 1/2 · NCT01861496 Completed
PARP inhibitor 2X-121 Metastatic Breast Cancer Phase 2 · NCT03562832 Completed

Also used in these trials (approved or third-party drugs, not ALLR's own candidates): Ixabepilone.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ALLR holds $17M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.5M/quarter from operations, an estimated runway of 14.4 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 48 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALLR files for a raise →

👥 Who Owns ALLR

Insiders 8.2% Institutions (21 holders) 7.5% Public and other holders 84.3%
HolderTypeShares% of sharesAs of
Thomas Jensen
CEO
Insider 596,734 3.73% 2026-01-28
Jeremy R. Graff
President and Chief Development Officer · +269,122 options
Insider 381,644 2.39% 2026-01-28
Jeffrey S Ervin
CFO
Insider 150,000 0.94% 2026-01-28
Alexander Epshinsky
CFO
Insider 85,051 0.53% 2025-01-22
Gerald W. McLaughlin
Director · +50,000 options
Insider 70,000 0.44% 2026-01-28
Jesper Hoeiland
Director
Insider 25,000 0.16% 2026-01-28

Share count 15,997,108 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ALLR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALLR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.